HUBEI BIOCAUSE HEILEN PHARMACEUTICAL CO., LTD.

Hubei Biocause Heilen Pharmaceutical Co., Ltd.

301211

CNE100005782

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-06-06 pm EDT			5-day change	1st Jan Change
15.2 ^CNY	+1.67%		-7.32%	-30.11%

May. 17	Biocause Heilen Pharmaceutical's Cardiovascular Drug Passes Chinese Drug Regulator's Evaluation	MT
Apr. 28	Hubei Biocause Heilen Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Hubei Biocause Heilen Pharmaceutical Co., Ltd.(XSEC:301211) added to S&P Global BMI Index

September 18, 2023 at 12:00 am EDT

Latest news about Hubei Biocause Heilen Pharmaceutical Co., Ltd.

Biocause Heilen Pharmaceutical's Cardiovascular Drug Passes Chinese Drug Regulator's Evaluation	May. 17	MT
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 28	CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 22	CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-17	CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd.(XSEC:301211) added to S&P Global BMI Index	23-09-18	CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24	CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-24	CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-25	CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-29	CI

Chart Hubei Biocause Heilen Pharmaceutical Co., Ltd.

Duration

Period

Chart Hubei Biocause Heilen Pharmaceutical Co., Ltd.

More charts

Hubei Biocause Heilen Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of chemical Active Pharmaceutical Ingredients (API) and preparation products. The Company's products can be divided into non-steroidal anti-inflammatory, cardiovascular and anti-tumor. The API products include Ibuprofen, D-Ibuprofen, Torasemide, Milrinone, Abiraterone Acetate, Granisetron Hydrochloride, Fludarabine Phosphate and others. The preparation products include Ibuprofen Granules, Ibuprofen Tablets, Ibuprofen Pseudoephedrine Tablets, Oxaprozin Enteric Coated Tablets, Oxaprozin Enteric Coated Capsules, Torasemide Tablets and others. The Company's products are exported to India, the United States, the European Union, South Korea and other countries.

Sector

Pharmaceuticals

Calendar

2024-08-26 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HUBEI BIOCAUSE HEILEN PHARMACEUTICAL CO., LTD.	-30.11%	604M
ELI LILLY AND COMPANY	+45.82%	765B
NOVO NORDISK A/S	+40.95%	632B
JOHNSON & JOHNSON	-6.16%	354B
MERCK & CO., INC.	+19.86%	331B
ABBVIE INC.	+9.32%	299B
ASTRAZENECA PLC	+18.45%	248B
ROCHE HOLDING AG	-0.78%	219B
NOVARTIS AG	+11.88%	216B
AMGEN INC.	+5.90%	164B